Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing‐remitting multiple sclerosis patients

• Published in: Journal of pineal research Vol. 63; no. 4
• Main Authors: Álvarez‐Sánchez, Nuria, Cruz‐Chamorro, Ivan, Díaz‐Sánchez, María, Sarmiento‐Soto, Helia, Medrano‐Campillo, Pablo, Martínez‐López, Alicia, Lardone, Patricia J., Guerrero, Juan M., Carrillo‐Vico, Antonio
• Format: Journal Article
• Language: English
• Published: England 01.11.2017
• Subjects: acetylserotonin O‐methyltransferase; Adult; Antioxidants - pharmacology; arylalkylamine N‐acetyltransferase; Cells, Cultured; Female; Humans; IL‐22; Inflammation - immunology; Male; melatonin; Melatonin - pharmacology; melatonin receptors; multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - immunology; T-Lymphocytes, Helper-Inducer - drug effects; Th1 response; Th1 response; acetylserotonin O-methyltransferase; arylalkylamine N-acetyltransferase; multiple sclerosis; melatonin; melatonin receptors; IL-22
• ISSN: 0742-3098; 1600-079X; 1600-079X
• DOI: 10.1111/jpi.12442

Multiple sclerosis (MS) is a neuroinflammatory disease of the central nervous system in which the immune system plays a central role. In particular, effector populations such as T helper (Th) 1, Th9, Th17, and Th22 cells are involved in disease development, whereas T regulatory cells (Tregs) are associated with the resolution of the disease. Melatonin levels are impaired in patients with MS, and exogenous melatonin ameliorates the disease in MS animal models by modulating the Th1/Th17/Treg responses and also improves quality of life and several symptoms in patients with MS. However, no study has examined melatonin's effect on T cells from relapsing‐remitting MS (RR‐MS) patients. Therefore, the objectives of the present study were to evaluate the effects of the in vitro administration of melatonin to peripheral blood mononuclear cells (PBMCs) from 64 RR‐MS patients and 64 sex‐ and age‐matched healthy subjects on Th1, Th9, Th17, Th22, and Treg responses and to analyze the expression of the melatonin effector/receptor system in these cells. Melatonin decreased Th1 and Th22 responses in patients, whereas it did not affect the Th17 and Treg subsets. Melatonin also promoted skewing toward a more protective cytokine microenvironment, as shown by an increased anti‐inflammatory/Th1 ratio. Furthermore, for the first time, we describe the overexpression of the melatonin effector/receptor system in PBMCs from patients with MS; this alteration might be relevant to the disease because acetylserotonin O‐methyltransferase expression significantly correlates with disease progression and T effector/regulatory responses in patients. Therefore, our data suggest that melatonin may be an effective treatment for MS.